REPL on Nasdaq

Replimune Group, Inc.

American biological products company based in Woburn, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$313.9MNet income, fiscal 2026²

Compare with another stock.

TickerREPL on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersWoburn, United States
Incorporated inDE³
Business address500 Unicorn Park, Woburn, Ma 01801³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-188.9%Return on equity²

0.50×Debt to equity²

Financial statements

Operating income⁴⁵⁶⁷⁸⁹²-$319.9M in 2026+934% since 2019

Net income⁴⁵⁶⁷⁸⁹²-$313.9M in 2026+918% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2026-03-31	2025-03-31
Research and development	$221.2M	$189.4M
Selling, general and administrative	$98.7M	$72.2M
Total operating expenses	$319.9M	$261.6M
Loss from operations	-$319.9M	-$261.6M
Research and development incentives	$1.6M	$1.8M
Investment income	$13.6M	$21.1M
Interest expense on finance lease liability	-$2.1M	-$2.1M
Interest expense on debt obligations	-$6.8M	-$5.8M
Other expense	-$942.0K	-$202.0K
Total other income, net	$5.4M	$14.8M
Loss before income taxes	-$314.5M	-$246.8M
Income tax (benefit) provision	-$551.0K	$468.0K
Net loss	-$313.9M	-$247.3M
Net loss per common share, basic (in dollars per share)	-$3.38	-$3.07
Net loss per common share, diluted (in dollars per share)	-$3.38	-$3.07
Weighted average common shares outstanding, basic (in shares)	92.8M shares	80.6M shares
Weighted average common shares outstanding, diluted (in shares)	92.8M shares	80.6M shares

Total assets⁴⁵⁶⁷⁸⁹²$332.4M in 2026+115% since 2019

Total liabilities⁴⁵⁶⁷⁸⁹²$166.2M in 2026+909% since 2019

Shareholders’ equity⁵⁶⁷⁸⁹²$166.2M in 2026+21% since 2019

Cash⁴⁵⁶⁷⁸⁹²$209.0M in 2026+713% since 2019

Long-term debt⁵⁷⁸⁹²$83.3M in 2026+750% since 2020

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2026-03-31	2025-03-31	2024-03-31
Cash and cash equivalents	$209.0M	$111.1M
Short-term investments	$59.9M	$372.7M
Research and development incentives receivable	$1.6M	$3.7M
Prepaid expenses and other current assets	$8.6M	$8.4M
Total current assets	$279.1M	$495.9M
Property, plant and equipment, net	$13.0M	$13.7M
Restricted cash	$1.7M	$1.7M
Other non-current assets	$2.9M	$1.2M
Right-of-use assetoperating leases	$3.3M	$4.0M
Right-of-use assetfinance leases	$32.4M	$34.8M
Total assets	$332.4M	$551.3M
Accounts payable	$6.7M	$12.5M
Accrued expenses and other current liabilities	$47.5M	$45.9M
Operating lease liabilities, current	$1.2M	$1.2M
Finance lease liabilities, current	$2.9M	$2.8M
Total current liabilities	$58.2M	$62.4M
Operating lease liabilities, non-current	$2.3M	$3.1M
Finance lease liabilities, non-current	$21.9M	$22.7M
Long term debt, net of discount	$83.3M	$46.4M
Other liabilities, non-current	$455.0K	$941.0K
Total liabilities	$166.2M	$135.5M
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and March 31, 2025; 82,716,923 and 77,085,024 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively	$82.0K	$77.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated deficit	-$1.3B	-$948.6M
Accumulated other comprehensive income	$5.4M	$5.4M
Total stockholders equity	$166.2M	$415.8M	$374.5M
Total liabilities and stockholders equity	$332.4M	$551.3M
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	150.0M shares	150.0M shares
Common stock, issued (in shares)	82.7M shares	77.1M shares
Common stock, outstanding (in shares)	82.7M shares	77.1M shares

Period ending	2026-03-31	2025-03-31	2024-03-31
Cash and cash equivalents	$209.0M	$111.1M
Short-term investments	$59.9M	$372.7M
Research and development incentives receivable	$1.6M	$3.7M
Prepaid expenses and other current assets	$8.6M	$8.4M
Total current assets	$279.1M	$495.9M
Property, plant and equipment, net	$13.0M	$13.7M
Restricted cash	$1.7M	$1.7M
Other non-current assets	$2.9M	$1.2M
Right-of-use assetoperating leases	$3.3M	$4.0M
Right-of-use assetfinance leases	$32.4M	$34.8M
Total assets	$332.4M	$551.3M
Accounts payable	$6.7M	$12.5M
Accrued expenses and other current liabilities	$47.5M	$45.9M
Operating lease liabilities, current	$1.2M	$1.2M
Finance lease liabilities, current	$2.9M	$2.8M
Total current liabilities	$58.2M	$62.4M
Operating lease liabilities, non-current	$2.3M	$3.1M
Finance lease liabilities, non-current	$21.9M	$22.7M
Long term debt, net of discount	$83.3M	$46.4M
Other liabilities, non-current	$455.0K	$941.0K
Total liabilities	$166.2M	$135.5M
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and March 31, 2025; 82,716,923 and 77,085,024 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively	$82.0K	$77.0K
Additional paid-in capital	$1.4B	$1.4B
Accumulated deficit	-$1.3B	-$948.6M
Accumulated other comprehensive income	$5.4M	$5.4M
Total stockholders equity	$166.2M	$415.8M	$374.5M
Total liabilities and stockholders equity	$332.4M	$551.3M
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	150.0M shares	150.0M shares
Common stock, issued (in shares)	82.7M shares	77.1M shares
Common stock, outstanding (in shares)	82.7M shares	77.1M shares

Cash from operations⁴⁵⁶⁷⁸⁹²-$280.3M in 2026+1005% since 2019

Capital spending⁴⁵⁶⁷$2.3M in 2023−13% since 2019

Free cash flow⁴⁵⁶⁷⁸-$130.3M in 2023+366% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2026-03-31	2025-03-31
Net loss	-$313.9M	-$247.3M
Stock-based compensation expense	$32.3M	$35.0M
Depreciation and amortization	$3.3M	$3.5M
Operating lease, right-of-use-asset amortization	$771.0K	$683.0K
Finance lease, right-of-use-asset amortization	$2.4M	$2.4M
Net amortization of premiums and discounts on short-term investments	-$2.5M	-$8.9M
Impairment on property, plant and equipment	$188.0K	$0
Noncash interest expense	$1.9M	$1.6M
Unrealized foreign currency transaction gains	-$942.0K	-$201.0K
Research and development incentives receivable	$451.0K	$1.3M
Prepaid expenses and other current assets	-$232.0K	-$252.0K
Other non-current assets	$0	-$1.2M
Accounts payable	-$4.9M	$9.9M
Accrued expenses and other current liabilities	$2.2M	$11.7M
Operating lease liabilities	-$818.0K	-$720.0K
Other non-current liabilities	-$487.0K	$155.0K
Net cash used in operating activities	-$280.3M	-$192.2M
Purchases of property, plant and equipment and software capitalization	-$4.2M	-$6.7M
Purchase of short-term investments	-$77.9M	-$403.6M
Proceeds from sales and maturities of short-term investments	$393.0M	$386.5M
Net cash provided by (used in) investing activities	$310.8M	-$23.8M
Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and offering costs	$0	$97.0M
Proceeds from long-term debt	$35.0M	$0
Principal payment of finance lease obligation	-$736.0K	-$599.0K
Proceeds from exercise of stock options and pre-funded warrants	$883.0K	$267.0K
Net cash provided by financing activities	$66.3M	$252.4M
Effect of exchange rate changes on cash, cash equivalents and restricted cash	$1.1M	$315.0K
Net increase in cash, cash equivalents and restricted cash	$97.9M	$36.7M
Cash paid during the period for interest	$4.7M	$4.2M
Cash received (paid) for income taxes, net	$5.0K	-$105.0K
Purchases of property and equipment included in accounts payable and accrued expenses	$80.0K	$171.0K

Compare Replimune Group, Inc. with another company

Leadership

Who has led Replimune Group, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Philip Astley-Sparke2018–2024

President

Robert Coffin2018–2023

Chief financial officer

Chief operating officer

Colin Love2018–2024

20202025

Chief executive officerSushil Patel Apr 3, 2024 to now¹³
Chief executive officerPhilip Astley-Sparke Apr 2, 2020 to May 18, 2023¹⁴
Chief executive officerRobert Coffin Sep 25, 2019 to Nov 8, 2019¹⁵
ChairPhilip Astley-Sparke Jul 19, 2018 to Aug 30, 2024¹⁶
PresidentRobert Coffin Jul 19, 2018 to May 18, 2023¹⁷
Chief financial officerEmily Luisa Hill Sep 20, 2023 to now¹⁸
Chief financial officerJean M. Franchi Dec 11, 2019 to May 18, 2023¹⁹
Chief operating officerColin Love Jul 19, 2018 to May 20, 2024²⁰

Board members and other officers (30)

Chief Accounting OfficerAndrew Schwendenman May 18, 2023 to now²¹
Chief Commercial OfficerChristopher Sarchi Jul 26, 2023 to now²²
Chief Medical OfficerKonstantinos Xynos Dec 5, 2022 to now²³
Chief Commercial OfficerSushil Patel May 5, 2021 to Jun 15, 2023²⁴
Chief Dev. Oper. Off.Tanya Lewis May 11, 2021 to Jun 15, 2023²⁵
Pres & Chief Res & Dev OfficerRobert Coffin Feb 14, 2020 to Apr 2, 2020²⁶
Chief Medical OfficerAndrea Pirzkall Jul 22, 2020 to Apr 5, 2021²⁷
Chief Medical OfficerHoward Kaufman Jul 19, 2018 to Dec 19, 2019²⁸
Chief Business OfficerPamela Esposito Jul 19, 2018 to Sep 13, 2023²⁹
Chief Accounting OfficerStephen A. Gorgol Jul 19, 2018 to Apr 2, 2020³⁰
Board memberFelix Baker Mar 7, 2025 to now³¹
Board memberJulian Baker Mar 7, 2025 to now³¹
Board memberL.p. 667 Mar 7, 2025 to now³¹
Board memberMichael Goller Mar 7, 2025 to now³²
Board memberSushil Patel Apr 3, 2024 to now¹³
Board memberMadhavan Balachandran Sep 5, 2024 to now³³
Board memberVeleka Peeples-Dyer Jun 5, 2023 to now³⁴
Board memberChristy J. Oliger Dec 3, 2021 to now³⁵
Board memberPaolo Pucci Apr 2, 2020 to now³⁶
Board memberPhilip Astley-Sparke Apr 2, 2020 to now¹⁴
Board memberTanya Lewis Nov 3, 2020 to Apr 5, 2021³⁷
Board memberDieter Weinand Jul 19, 2018 to now³⁸
Board memberHugo Alexander Slootweg Jul 19, 2018 to Apr 4, 2023³⁹
Board memberHyam Levitsky Jul 19, 2018 to Apr 3, 2024⁴⁰
Board memberJason P. Rhodes Jul 19, 2018 to Apr 5, 2022⁴¹
Board memberJoseph P. Slattery Jul 19, 2018 to now⁴²
Board memberKapil Dhingra Jul 19, 2018 to now⁴³
Board memberOtello Stampacchia Jul 19, 2018 to Nov 23, 2021⁴⁴
Board memberRobert Coffin Jul 19, 2018 to May 20, 2024¹⁷
Board memberAdam Koppel Jul 26, 2018 to Jul 26, 2018⁴⁵

Timeline

Apr 3, 2024New chief executive Sushil Patel becomes CEO¹³
Apr 2, 2020New chief executive Philip Astley-Sparke becomes CEO¹⁴
Sep 25, 2019New chief executive Robert Coffin becomes CEO¹⁵
Jul 5, 2017Founded Replimune Group, Inc. is founded⁴⁶

Filings

358 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 161 insider forms, 49 large holders, 62 other. The latest 20:

The 358 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 49 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Baker Bros. Advisors LP	11,045,336	$122.3M	0.6%	No change
BlackRock, Inc.	8,958,535	$99.2M	0.0%	+2,719,296
Rtw Investments, LP	7,411,581	$82.0M	0.7%	+54,665
Ridgeback Capital Investments L.P.	7,310,656	$80.9M	100.0%	New
Goldman Sachs Group Inc	4,541,018	$50.3M	0.0%	+2,263,742
State Street Corp	4,440,144	$49.2M	0.0%	+657,907
Montanova Capital, LLC	4,389,836	$48.6M	1.0%	+168,000
Boxer Capital Management, LLC	3,983,000	$44.1M	3.3%	+2,808,000
Vanguard Capital Management LLC	2,896,004	$32.1M	0.0%	+136,884
Fcpm III Services B.v.	2,808,368	$31.1M	4.1%	No change
Aqr Capital Management LLC	2,566,241	$28.4M	0.0%	+2,310,746
Logos Global Management LP	2,500,000	$27.7M	1.2%	New
Jane Street Group, LLC	2,322,545	$25.7M	0.0%	+1,894,400
Erste Asset Management GmbH	2,120,000	$23.7M	0.2%	No change
Geode Capital Management, LLC	2,035,187	$22.5M	0.0%	+233,662
D. E. Shaw & Co., Inc.	1,789,964	$19.8M	0.0%	−546,564
Opaleye Management Inc.	1,384,993	$15.3M	1.4%	New
Toronto Dominion Bank	1,275,000	$14.1M	0.0%	−316,030
UBS Group AG	1,128,276	$12.5M	0.0%	+547,066
Artisan Partners Limited Partnership	973,496	$10.8M	0.0%	New
Fmr LLC	929,375	$10.3M	0.0%	−1,116,115
Millennium Management LLC	821,958	$9.1M	0.0%	+521,125
Citadel Advisors LLC	784,233	$8.7M	0.0%	+385,504
Caption Management, LLC	783,873	$8.7M	0.3%	+332,051
Invesco Ltd.	724,244	$8.0M	0.0%	+533,319

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARReplimune Group, Inc. filings on SEC EDGAR
2
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2026
3
SEC EDGARReplimune Group, Inc. filings on SEC EDGAR
4
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2019
5
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2020
6
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2021
7
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2022
8
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2023
9
SEC EDGARReplimune Group, Inc. 10-K for fiscal 2024
10
SEC EDGARReplimune Group, Inc. 10-Q for fiscal 2025
11
SEC EDGARReplimune Group, Inc. 10-Q for fiscal 2025
12
SEC EDGARReplimune Group, Inc. 10-Q for fiscal 2026
13
SEC EDGARSushil Patel, Chief executive officer
14
SEC EDGARPhilip Astley-Sparke, Chief executive officer
15
SEC EDGARRobert Coffin, Chief executive officer
16
SEC EDGARPhilip Astley-Sparke, Chair
17
SEC EDGARRobert Coffin, President
18
SEC EDGAREmily Luisa Hill, Chief financial officer
19
SEC EDGARJean M. Franchi, Chief financial officer
20
SEC EDGARColin Love, Chief operating officer
21
SEC EDGARAndrew Schwendenman, Chief Accounting Officer
22
SEC EDGARChristopher Sarchi, Chief Commercial Officer
23
SEC EDGARKonstantinos Xynos, Chief Medical Officer
24
SEC EDGARSushil Patel, Chief Commercial Officer
25
SEC EDGARTanya Lewis, Chief Dev. Oper. Off.
26
SEC EDGARRobert Coffin, Pres & Chief Res & Dev Officer
27
SEC EDGARAndrea Pirzkall, Chief Medical Officer
28
SEC EDGARHoward Kaufman, Chief Medical Officer
29
SEC EDGARPamela Esposito, Chief Business Officer
30
SEC EDGARStephen A. Gorgol, Chief Accounting Officer
31
SEC EDGARFelix Baker, Board member
32
SEC EDGARMichael Goller, Board member
33
SEC EDGARMadhavan Balachandran, Board member
34
SEC EDGARVeleka Peeples-Dyer, Board member
35
SEC EDGARChristy J. Oliger, Board member
36
SEC EDGARPaolo Pucci, Board member
37
SEC EDGARTanya Lewis, Board member
38
SEC EDGARDieter Weinand, Board member
39
SEC EDGARHugo Alexander Slootweg, Board member
40
SEC EDGARHyam Levitsky, Board member
41
SEC EDGARJason P. Rhodes, Board member
42
SEC EDGARJoseph P. Slattery, Board member
43
SEC EDGARKapil Dhingra, Board member
44
SEC EDGAROtello Stampacchia, Board member
45
SEC EDGARAdam Koppel, Board member
46
gleifReplimune Group, Inc. is founded